Vertex Q4 EPS $5.03 Misses by $0.04; Revenue Rises 9.6% to $3.19B
Vertex Pharmaceuticals reported adjusted Q4 EPS of $5.03, missing estimates by $0.04, while revenue rose 9.6% year-over-year to $3.19 billion, beating consensus by 0.7%. Consensus for Q1 calls for $4.65 EPS on $3.11 billion revenue, and FY2026 estimates stand at $19.92 EPS on $12.91 billion.
1. Earnings Miss Expectations
Vertex Pharmaceuticals reported adjusted Q4 EPS of $5.03, falling short of the $5.07 consensus by $0.04 and delivering a -0.74% earnings surprise.
2. Revenue Beats Consensus
Revenue for Q4 rose 9.6% year-over-year to $3.19 billion, surpassing the consensus target by 0.7% and marking the third top-line beat in four quarters.
3. Forward Guidance and Consensus Estimates
Analyst consensus for Q1 projects $4.65 EPS on $3.11 billion in sales, while full-year FY2026 forecasts stand at $19.92 EPS on $12.91 billion in revenue.
Related News
BBVA
BBVA Joins 25 Banks in 37-Member Qivalis Euro Stablecoin Consortium
BBVA•
META
Meta Secures Tens of Thousands MWh Storage Deals, Cuts 10% Workforce
META•
FDS
Nvidia Q1 Revenue Soars 85% to $81.6B as Buyback Approved
FDS•
NVDA
NVIDIA Forecasts Zero China Data Center Revenue, Targets $20B Vera CPU Sales
NVDA•
GROW
US Global Investors Sees 15% AUM Gain, 31% Revenue Growth and $2.6M Profit
GROW•
Sources
F